Guidelines for Carcinoid Tumours Management
Author Information
Author(s): Maroun J. MD, Kocha W. MD, Kvols L. MD, Bjarnason G. MD, Chen E. MD, Germond C. MD, Hanna S. MD, Poitras P. MD, Rayson D. MD, Reid R. MD, Rivera J. MD, Roy A. MD, Shah A. MD, Sideris L. MD, Siu L. MD, Wong R. MD
Primary Institution: Ottawa Hospital Regional Cancer Centre
Conclusion
Proper management of carcinoid tumours can lead to improved patient outcomes and quality of life.
Supporting Evidence
- Carcinoid tumours represent less than 0.25% of the oncology patient load in Canada.
- Better diagnostic techniques have contributed to improved survival rates.
- Somatostatin analogues are first-line agents in the management of carcinoid syndrome.
- Debulking surgery can improve survival and quality of life for patients with carcinoid tumours.
- Patients with carcinoid syndrome should have an echocardiogram at diagnosis.
Takeaway
Carcinoid tumours are rare and can be managed effectively with the right treatments, which can help patients live longer and feel better.
Methodology
The guidelines were developed by a group of Canadian experts based on their clinical experience and existing literature.
Potential Biases
Limited experience of physicians with carcinoid tumours may introduce bias in management practices.
Limitations
The guidelines may not cover all aspects of carcinoid tumour management due to the rarity of the condition.
Participant Demographics
The guidelines are based on practices in Canada, with a focus on the Canadian healthcare context.
Want to read the original?
Access the complete publication on the publisher's website